Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613064 | 0.82 | PTGES2 (0.44) | CCR2PTGES2ACLYCA2CA9 | |
| SCHEMBL6615166 | 0.81 | HSD11B1 (0.54) | CCR2MCL1ACLYHSD11B1 | |
| SCHEMBL6615454 | 0.80 | MCL1 (0.38) | CCR2MCL1PTGES2ACLYEGFR | |
| SCHEMBL6612056 | 0.77 | MCL1 (0.44) | CCR2MCL1PTGES2ACLY | |
| SCHEMBL5831691 | 0.76 | FBP1 (0.39) | MCL1PTGES2CA2CA9KMT2A | |
| SCHEMBL2763190 | 0.76 | KDM1A (0.45) | KMT2AMEN1HSD11B1FBP1 | |
| SCHEMBL5229967 | 0.75 | P2RX1 (0.47) | MCL1PTGES2ACLYCA2CA9 | |
| SCHEMBL5229776 | 0.74 | MEN1 (0.55) | MCL1CA2KMT2AMEN1FBP1 | |
| SCHEMBL5830671 | 0.74 | FBP1 (0.37) | MCL1PTGES2EGFRKMT2AMEN1 | |
| SCHEMBL6612189 | 0.73 | PTGES2 (0.40) | CCR2PTGES2ACLYCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | CCR2 4726/4885MCL1 3245/4885PTGES2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.